Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.51 |
| ▸ | MTOR | P42345 | 9/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556220 | 1.00 | PIK3CD (0.53) | PIK3CDPIK3CAMTORPIK3R1AKT1 | |
| SCHEMBL29555684 | 0.89 | PIK3CD (0.57) | PIK3CDPIK3CAMTORPIK3R1 | |
| SCHEMBL3115744 | 0.89 | PIK3CD (0.57) | PIK3CDPIK3CAMTORPIK3R1 | |
| SCHEMBL28578763 | 0.88 | PIK3CG (0.44) | PIK3CDPIK3CAMTORPIK3R1 | |
| SCHEMBL28603141 | 0.87 | PIK3CA (0.40) | PIK3CDPIK3CAMTORAKT1 | |
| SCHEMBL12276481 | 0.87 | PIK3CD (0.57) | PIK3CDPIK3CAMTOR | |
| SCHEMBL29556116 | 0.87 | PIK3CD (0.57) | PIK3CDPIK3CAMTOR | |
| SCHEMBL1544034 | 0.87 | LMNA (0.46) | PIK3CDPIK3CAMTORPIK3R1AKT1 | |
| SCHEMBL12724541 | 0.86 | PIK3CD (0.48) | PIK3CDPIK3CAMTORPIK3R1AKT1 | |
| SCHEMBL15559069 | 0.85 | ALPL (0.52) | PIK3CDPIK3CAMTORPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481822-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-112724134-B | Azaindazole bipyridine derivative myeloid cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2022-04-01 | — | — | CN | disclosed |
| CN-113214247-A | Azaindole derivative marrow cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2021-08-06 | — | — | CN | disclosed |
| CN-112724134-A | Azaindazole bipyridine derivative myeloid cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2021-04-30 | — | — | CN | disclosed |
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2307400-B1 | INHIBITORS OF PI3 KINASE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| EP-2183232-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | Amgen, Inc (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | REN, ACE, AGTR2 | PIK3CD 1639/4885PIK3CA 1232/4885MTOR 3521/4885 |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | PIK3CD 4/4885PIK3CA 1/4885MTOR 37/4885 |
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | MTOR, PIK3CA, MAPKAP1 | PIK3CD 10/4885PIK3CA 2/4885MTOR 1/4885 |
| US-20090163489-A1 | Inhibitors of PI3 kinase | PIK3CA, PIK3CD, PIK3CG | PIK3CD 2/4885PIK3CA 1/4885MTOR 28/4885 |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | MTOR, PIK3CA, MAPKAP1 | PIK3CD 10/4885PIK3CA 2/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.